Researchers at RMIT University have described collecting bronchial brushings as part of a molecular approach that may enable diagnosing lung cancer patients and guiding therapies.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
Roche said at the AMP annual meeting that it plans to commercialize the system in Europe with CE IVD marking for clinical applications and in the US with a 510(k) exemption.
